These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 35650458)
1. Gepants - a long way to cure: a narrative review. Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313 [TBL] [Abstract][Full Text] [Related]
3. Update of Gepants in the Treatment of Chronic Migraine. Cho S; Kim BK Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319 [TBL] [Abstract][Full Text] [Related]
4. The pharmacotherapeutic management of episodic and chronic migraine with gepants. Tajti J; Szok D; Csáti A; Vécsei L Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933 [TBL] [Abstract][Full Text] [Related]
9. A Brief Review of Gepants. Li D; Abreu J; Tepper SJ Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032 [TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Chiang CC; Schwedt TJ Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505 [TBL] [Abstract][Full Text] [Related]
11. Atogepant: an emerging treatment for migraine. Rustichelli C; Avallone R; Ferrari A Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319 [TBL] [Abstract][Full Text] [Related]
12. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830 [TBL] [Abstract][Full Text] [Related]
13. Atogepant: Mechanism of action, clinical and translational science. Boinpally R; Shebley M; Trugman JM Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063 [TBL] [Abstract][Full Text] [Related]
15. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review. Dos Santos JBR; da Silva MRR Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493 [TBL] [Abstract][Full Text] [Related]
16. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325 [TBL] [Abstract][Full Text] [Related]
17. Update on gepants for the treatment of chronic migraine. Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548 [TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047 [TBL] [Abstract][Full Text] [Related]
20. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. Cohen F; Yuan H; Silberstein SD BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]